西妥昔单抗联合放疗治疗低危HPV相关口咽癌及不适合顺铂的头颈鳞癌的配对II期试验
本研究开展配对II期试验,评估西妥昔单抗联合放疗在低危HPV阳性口咽癌(队列A)和顺铂不耐受患者(队列B)中的毒性和疗效。中位随访48个月,队列A的2年无病生存率为81%,队列B因不良结局提前关闭,2年无病生存率仅37%。60%患者出现严重毒性,30%需要肠内营养,提示西妥昔单抗并非良性治疗。
要点
- 低危HPV阳性口咽癌患者接受西妥昔单抗联合放疗的2年无病生存率为81%。
- 顺铂不耐受患者接受西妥昔单抗联合放疗的2年无病生存率仅37%,试验提前关闭。
- 60%患者出现严重毒性,30%需要肠内营养,毒性程度与含铂方案相当。
核心结论
- 在顺铂不耐受患者中,西妥昔单抗联合放疗的疗效较差。
- 西妥昔单抗联合放疗的严重毒性发生率与含铂方案相当,并非良性治疗。
研究设计与样本
- 配对II期试验,评估西妥昔单抗联合放疗在两个队列中的毒性和疗效。
- 队列A为低危HPV阳性口咽癌,队列B为顺铂不耐受患者。
主要发现
- 队列A的2年无病生存率为81%。
- 队列B的2年无病生存率为37%。
- 60%的患者出现严重毒性,30%需要肠内营养。
临床怎么用
- 对于顺铂不耐受的头颈鳞癌患者,西妥昔单抗联合放疗可能疗效不佳,需谨慎选择。
- 西妥昔单抗联合放疗的严重毒性不容忽视,治疗期间应密切监测营养状况和毒性反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alternative therapeutic strategies are needed for localized oropharyngeal carcinoma. Cetuximab represents a potential option for those ineligible for cisplatin or, until recently, an agent for de-escalation in low risk HPV+ oropharyngeal carcinoma (OPSCC). Our objective was to define the toxicity and efficacy of cetuximab-radiotherapy. METHODS: We conducted paired phase II trials evaluating cetuximab-radiotherapy in two cohorts (a) low risk HPV+ OPSCC and (b) cisplatin ineligible. The mean follow-up was 48 months. RESULTS: Forty-two patients were enrolled in cohort A with a 2-year disease free survival (DFS) of 81%. Twenty-one patients were enrolled in cohort B prior to closure due to adverse outcomes with a 2-year DFS of 37%. Severe toxicities were seen in 60% of patients, 30% required enteral nutrition. CONCLUSION: Among cisplatin ineligible patients, cetuximab treatment engendered poor outcomes. Rates of severe toxicities were on par with platinum-based regimens suggesting that cetuximab is not a benign treatment.
引用
- Swiecicki PL, Li P, Bellile E, et al. Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. Head Neck. 2020. PMID: 31989702. doi:10.1002/hed.26085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。